Importantly, findings from the BOLERO-2 trial demonstrated that treatment with everolimus in conjunction with aromatase inhibitor exemestane significantly improved the overall response rate in patients with HR+ advanced cancer that had previously been treated with nonsteroidal aromatase inhibitors, and its activity was irrespective of PI3K genetic alterations [64]. Here, CYP19A1 is linked to cancer.